NCT00631800已完成2 期
Phase II Randomized, Double Blind, Placebo Controlled, Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110, for the Prevention of Staphylococcal Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Safety and pharmacokinetics
研究概览
简要总结
The purpose of this study is to evaluate the safety (including tolerability), pharmacokinetics, pharmacodynamics and clinical activity of BSYX-A110 administered in a 3-dose regimen on Study Days 0, 7, and 14.
详细描述
This Phase II study will be a randomized, double blind, placebo controlled study of BSYX-A110 in very low birth weight neonates. A total of 80 infants will be dosed in this study. Participants will receive either BSYX-A110 or placebo, at 60 mg/kg or 90 mg/kg. The Study Drug will be administered at 48-120 hours of life, 7 days after the initial dose, and 14 days after the initial dose for all dose groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 48 Hours 至 120 Hours（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients must meet all of the following criteria at the time of first infusion (Day 0):
- •48-120 hours of age, inclusive
- •Birth weight of 700-1300 grams
- •Inpatient in a Neonatal Intensive Care Unit
- •Written informed consent obtained from the parent(s) or legal guardian
- •Multiple gestations:
- •Siblings from multiple gestations may be enrolled if they each meet the entry criteria
- •No more than 4 subjects in any birth weight cohort may be siblings
排除标准
- •Patients may have none of the following at the first dose:
- •Survival not expected for at least 1 week after infusion
- •Clinically overt systemic infection, as determined by history, physical examination, and positive culture from a normally sterile site. (Infuse only when infant clinically stable and cultures negative for 48 hours. If being evaluated for sepsis, decision to infuse may be deferred as allowed by protocol infusion window. Infusions outside of protocol window must be approved by Sponsor.)
- •Severe congenital anomalies or genetic disorders that are likely to be fatal or that may interfere with drug distribution or metabolism, as determined by history and/or physical examination, and including but not limited to:
- •i. Trisomy 13 ii. Trisomy 18 iii. Hypoplastic Left Heart Syndrome iv. Omphalocele v. Gastroschesis vi. Holoprosencephaly
- •Known or suspected hepatic or renal insufficiency
- •Clinically uncontrolled seizures
- •Immunodeficiency other than due to prematurity
- •A history of standard immune globulin administration prior to first study drug infusion (excluding Hepatitis B Immune Globulin, HBIG)
- •Any history, in the infant subject or its mother, of a hypersensitivity or severe vasomotor reaction to immunoglobulin G, or blood products
- •Currently receiving, recently received, or planned to receive other investigational agents that could interfere with conduct or results of this study; including enrollment in another investigational study for a product under an IRB-approved protocol
- •Expectation that the patient will not be able to be followed for the duration of the study
- •Mother with serology positive for hepatitis B surface antigen
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Pagibaximab (formerly BSYX-A110) (Drug)
60 mg/kg
Experimental
60 mg/kg was given on Days 0, 7, 14
干预措施: Pagibaximab (formerly BSYX-A110) (Drug)
90 mg/kg
Experimental
90 mg/kg was given on Days 0, 7, 14
干预措施: Pagibaximab (formerly BSYX-A110) (Drug)
结局指标
主要结局
Safety and pharmacokinetics
时间窗: 0 - 56 days
次要结局
- Pharmacodynamics, sepsis/bloodstream infection(0 - 56 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCVHCV InfectionNCT00725803Gilead Sciences33
进行中（未招募）
1 期
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Myotonic Dystrophy Type 1 (DM1)NCT06185764Vertex Pharmaceuticals Incorporated47
撤回
2 期
Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery PatientsCardiopulmonary BypassHypotensionNCT00482287Meditor Pharmaceuticals Ltd.
终止
2 期
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisDiffuse Cutaneous Systemic SclerosisNCT02465437Corbus Pharmaceuticals Inc.42
已完成
2 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic FibrosisCystic FibrosisNCT02465450Corbus Pharmaceuticals Inc.85